XTL BIOPHARMACEUTICALS-ADR (XTLB) Forecast, Price Target & Analyst Ratings

NASDAQ:XTLB • US98386D3070

0.775 USD
+0.01 (+1.35%)
At close: Mar 3, 2026
0.7733 USD
0 (-0.22%)
After Hours: 3/3/2026, 8:00:02 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for XTL BIOPHARMACEUTICALS-ADR (XTLB).

Forecast Snapshot

Consensus Price Target

Price Target
N/A
N/A

Next Earnings Forecast

Earnings Estimate
Release DateN/A

ChartMill Buy Consensus

Rating
0.00%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
N/A
Upside
N/A
From current price of $0.78 to mean target of N/A, Based on 0 analyst forecasts
Low
N/A
Median
N/A
High
N/A

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus
0.00%
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release DateN/A

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2015 2016 2017 2018
Revenue
YoY % growth
XTLB revenue by date.XTLB revenue by date.
EBITDA
YoY % growth
XTLB ebitda by date.XTLB ebitda by date.
-2M-1.71M
14.50%
-1.25M
26.90%
N/A
EBIT
YoY % growth
XTLB ebit by date.XTLB ebit by date.
-2.01M-1.71M
14.93%
-1.25M
26.90%
-790K
36.80%
Operating Margin
XTLB operating margin by date.XTLB operating margin by date.
N/AN/AN/AN/A
EPS
YoY % growth
XTLB eps by date.XTLB eps by date.
N/AN/AN/AN/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

XTL BIOPHARMACEUTICALS-ADR / XTLB Forecast FAQ